POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a multicenter Phase Ib/II, open-label, dose-escalation study to optimize POL6326 (balixafortide) in combination with nab-paclitaxel or eribulin in patients with HER2-negative advanced breast cancer.
Epistemonikos ID: 8b35cecd21179021b1ab409c11081d93972f6a36
First added on: May 08, 2024